Henry Schein has outlined its roadmap for 2026 which centres on improving profitability and expanding high margin businesses, at the ongoing J.P. Morgan Healthcare Conference held from 12 to 15 January, 2026.
The company, a leading provider of medical products, equipment, and services in the alternative care and home care markets, is focusing on shifts in healthcare delivery while tightening operational costs. Henry Schein currently has a broad portfolio with over $3bn in corporate and owned brand products and services.
Go deeper with GlobalData
Access deeper industry intelligence
Experience unmatched clarity with a single platform that combines unique data, AI, and human expertise.
Patient traffic is steadily rising across the medical market, and there has been a shift to outpatient care, as well as increased demand for chronic disease management and preventative healthcare. The company expects to see mid-single digit growth in the medical sector, with growth largely driven by increases in market share.
The company reports a strong cash flow, with a non-GAAP earnings per diluted share compound annual growth rate of 6.2%. Henry Schein recent capital deployment has focused on share repurchases, reflecting future outlooks on the company’s long-term earning potential.
Henry Schein has also set out the goal to deliver more than $200m in operating income improvements over the next few years. This goal is expected to be met through a combination of lower costs and higher gross margins. Henry Schein is targeting reductions in global selling, general, and administrative costs by expanding shared services and streamlining operations across its various acquisitions. Henry Schein is also pursuing pricing focused initiatives and accelerating the growth of its corporate brands.
Henry Schein’s long-term strategy is set out by their BOLD +1 strategy (Build, Operationalise, Leverage, Drive Digital). The company aims for 50% of its non-GAAP operating income to come from high-growth, high-margin businesses by the end of 2027, with an additional 10% coming from their corporate brands. In implementing this strategy, Henry Schein hopes to increase penetration amongst existing customers, expand its corporate brand offerings, growing its home care solutions, and continue expanding geographically. For its global specialty products, the company plans to continue developing brand owned products, develop specialised sales teams, and pursue further acquisitions.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe biggest announcement of the J.P. Morgan Healthcare Conference this January that Henry Schein made was a change in management lineup. Fred Lowery will become CEO of Henry Schein effective 2 March, 2026. Lowery currently serves as Executive Vice President and President of Laboratory Products and BioProduction at Thermo Fisher Scientific and brings 20 years of healthcare experience, including building high performance distribution organisations.
Sign up here to receive daily updates on the latest healthcare industry trends emerging from the JP Morgan Healthcare Conference 2026. Sign up here to receive a comprehensive report after the conference.
